X. Long Zheng, MD, PhD, details the typical healthcare costs for acquired TTP, the treatment options available to patients, and the goals of the healthcare provider. X. Long Zheng, MD, PhD: What does ...

X. Long Zheng, MD, PhD, discusses the unmet needs of acquired TTP, and the future of treatment. X. Long Zheng, MD, PhD: What are the unmet needs in acquired TTP [thrombotic thrombocytopenic purpura] ...

Thrombotic Thrombocytopenic Purpura (TTP) is a rare disorder caused by an enzyme deficiency. This can be heriditary or can be acquired as an autoimmune condition. Due to the associated excessive ...

In a new study by Yale Cancer Center (YCC) researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Takeda’s Biologics License Application (BLA) ...

Ablynx NV will evaluate accelerated approval in the U.S. and Europe for its most advanced product in early 2015 and is starting initial talks for Japan, Chief Executive Officer Edwin Moses said in an ...

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms Takeda Continues 70-plus Year Legacy of Driving Innovation for the Rare ...

Rare but deadly, thrombotic thrombocytopenic purpura (TTP) is a disease where blood clots block the smallest blood vessels often leading to kidney failure, stroke, and heart disease. Over 4 million ...